Company Overview and News
KUALA LUMPUR (Oct 19): MIDF Amanah Investment Bank Bhd Equity Research has maintained its "neutral" rating (NR) on the logistics sector, and said it does discount the possibilities of last-mile delivery players and e-commerce platforms participating in the Digital Free Trade Zone (DFTZ).
0078 7117 5267 7210
GD Express Carrier Bhd (Oct 8, 42 sen) Maintain neutral with a revised target price (TP) of 46 sen: GD Express Carrier Bhd (GDex) had subscribed to 44.5% of shares in PT SAP Express Tbk (SAP) listed on the development board of the Indonesian stock exchange last Wednesday for RM25.8 million.
KUALA LUMPUR (Oct 3): The FBM KLCI is seen hovering below the 1,800-point level today,tracking the overnight close at most gobal markets, exacerbated by tepid local investor sentiment.
0078 0143 5236 7811 MGFCF MSCI 9113
KUALA LUMPUR (Oct 2): Based on corporate announcements and news flow today, companies in focus on Wednesday (Oct 3) may include: Key ASIC Bhd, GD Express Carrier Bhd, Malakoff Corp Bhd, DRB-Hicom Bhd, Malaysia Marine and Heavy Engineering Holdings Bhd, Malton Bhd, Matrix Concepts Holdings Bhd, Mega First Corp Bhd, Sanbumi Holdings Bhd and Sapura Industrial Bhd.
0078 0143 5236 7811 MGFCF 9113
KUALA LUMPUR (Oct 2): GD Express Carrier Bhd (GDex) said today it will subscribe for 44.5% in the initial public offering (IPO) of PT Satria Antaran Prima Tbk (SAP Express) for 92.71 million rupiah (RM25.77 million) or 250 rupiah per share.
0078 BSMAF 1818
GD Express Carrier Bhd (Sept 7, 42 sen) Maintain neutral with an unchanged target price of 44 sen: To recall, GD Express Carrier Bhd’s (GDEx) normalised net profit for financial year 2018 (FY18) declined by -32.4% year-on-year (y-o-y) to RM25.1 million. This was mainly due to the higher annual tax rate of 47% (versus 17% in FY17) subsequent to the expiry of the pioneer status tax incentive on Sept 25, 2017 and the additional provision to address the possible clawback of the tax incentive post equity structure change in Yamato since February 2016.
KUALA LUMPUR (Aug 30): GD Express Carrier Bhd (GDex) closed its fourth quarter ended June 30, 2018 (4QFY18) with net profit declining 43% to RM6.52 million from RM11.51 million a year ago, dragged by higher operating expenses as the group undertook aggressive network expansion, as well as due to higher taxation.
ALIBABA Group opened an office in Bangsar South, Kuala Lumpur, last Monday — a reflection of the group’s commitment to Malaysia. While he was in town for the opening, executive chairman Jack Ma met Prime Minister Tun Dr Mahathir Mohamad in Putrajaya for an hour.
4634 0078 MYPRY 8397 BSMAF 5014 1818
KUALA LUMPUR: Petronas Chemicals Group Bhd (PetChem), IHH Healthcare Bhd , Inta Bina Group Bhd, Harrisons Holdings (M) Bhd and GD Express Carrier Bhd are among the stocks to watch on Thursday, according to JF Apex Research.
5008 0078 5225 5183 FORTIS PECGF Q0F IHHHF 532843
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...